Morningside’s Gerald Chan Joins Board of Aduro BioTech

Aduro BioTech, a Berkeley California clinical-stage cancer-immunotherapy company, has added Gerald Chan, DSc to its board of directors. Dr. Chan is Chairman and Co-founder of Morningside Group, a private investment group with investments in life science and other areas. Morningside has been an investor in Aduro from the start, and recently participated in Aduro’s $55 million C funding round along with new investor Johnson & Johnson Development Corporation. More details.... Share this with colleagues: // //